Biotechnological war against biofilms. Could phages mean the end of device-related infections?
Microorganisms universally attach to surfaces, resulting in biofilm formation. These biofilms entail a serious problem in daily clinical practice because of the great prevalence of implantable device-related infections. Differences in antibiotic activity against planktonic and sessile bacteria may relate to clinical failures in the treatment of biofilm-related infections (BRI). Bacteriophages have several characteristics that make them potentially attractive therapeutic agents in some selected clinical settings, like for example BRI. They are highly specific and very effective in lysing targeted bacteria, moreover, they appear to be safe for humans. Many studies have shown the potential of phages for the treatment of infectious diseases in plants and animals, including infections with highly drug-resistant bacteria. The therapeutic use of bacteriophages, possibly in combination with antibiotics, may be a valuable approach in BRI. However, many important questions still remain that must be addressed before phages can be endorsed for therapeutic use in humans.
Del Pozo
J L
JL
Division of Infectious Diseases and Clinical Microbiology, Clínica Universitaria de Navarra, Pamplona, Spain. jldelpozo@unav.es
Alonso
M
M
Arciola
C R
CR
Gonzalez
R
R
Leiva
J
J
Lasa
I
I
Penades
J
J
D000900:Anti-Bacterial Agents / Q000494:pharmacology / Q000627:therapeutic use; D010582:Bacteriophage lambda; D018441:Biofilms / Q000187:drug effects; D001709:Biotechnology / Q000379:methods*; D016459:Prosthesis-Related Infections / Q000382:microbiology / Q000517:prevention & control*; D013204:Staphylococcus Phages; D013211:Staphylococcus aureus / Q000187:drug effects / Q000254:growth & development / Q000821:virology*; D014640:Vancomycin / Q000494:pharmacology / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D014640:Vancomycin